Your browser doesn't support javascript.
loading
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.
Gargett, Tessa; Yu, Wenbo; Dotti, Gianpietro; Yvon, Eric S; Christo, Susan N; Hayball, John D; Lewis, Ian D; Brenner, Malcolm K; Brown, Michael P.
Afiliação
  • Gargett T; Translational Oncology Laboratory Centre for Cancer Biology, SA Pathology, and University of South Australia, Adelaide, South Australia. Electronic address: Tessa.Gargett@health.sa.gov.au.
  • Yu W; Translational Oncology Laboratory Centre for Cancer Biology, SA Pathology, and University of South Australia, Adelaide, South Australia.
  • Dotti G; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Feigin Center, Houston, Texas, USA; Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina
  • Yvon ES; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Feigin Center, Houston, Texas, USA; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Christo SN; Experimental Therapeutics Laboratory, Sansom Institute and Hanson Institute, School of Pharmacy and Medical Science, University of South Australia, Adelaide, South Australia.
  • Hayball JD; Experimental Therapeutics Laboratory, Sansom Institute and Hanson Institute, School of Pharmacy and Medical Science, University of South Australia, Adelaide, South Australia; Robinson Research Institute, Discipline of Obstetrics and Gynecology, School of Medicine, University of Adelaide, Adelaide, S
  • Lewis ID; Discipline of Medicine, University of Adelaide, Adelaide, South Australia.
  • Brenner MK; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Feigin Center, Houston, Texas, USA.
  • Brown MP; Translational Oncology Laboratory Centre for Cancer Biology, SA Pathology, and University of South Australia, Adelaide, South Australia; Discipline of Medicine, University of Adelaide, Adelaide, South Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia.
Mol Ther ; 24(6): 1135-1149, 2016 Jun.
Article em En | MEDLINE | ID: mdl-27019998
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article